Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

Summary

This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin) alters cardiac metabolism compared to placebo in a single blinded (to subject), randomized, parallel group, active controlled, single center experimental design.

Timeline

Start

2020-03-01

Primary completion

2023-01-11

Completion

2023-01-11

Drugs

Indications